Quanterix’s fifth-generation digital immunoassay prostate specific antigen (PSA) test, demonstrated a 2-log improvement in sensitivity to measure PSA levels in patients following a radical prostatectomy.

The new PSA test based on proprietary single molecule array technology, forms a reliable predictor of five-year biochemical recurrence-free survival in men who have undergone radical prostatectomy for prostate cancer.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Quanterix Product Development senior director David Wilson said that the PSA assay could improve patient prognosis and inform clinical decisions for use of secondary therapy in individuals who have been treated surgically.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact